Financial Runway Extended during Q3 as Revenue Growth Continues
“Q3 2022 represented IRRAS’ 9th consecutive quarter of revenue growth, and the quarterly revenue of MSEK 11.0 represented 13% growth over Q2 2022 and 80% growth from the same period last year.”
“With the company’s financial runway extended, increasing customer adoption and proving the clinical superiority of our products are now our top two priorities, and we are excited to continue to deliver such results in coming quarters.“
Will Martin, CEO of IRRAS
Third quarter, July – September 2022
Period, January – September 2022
Significant events during the quarter
Rights issue of MSEK 215 completed
Short-term financing agreement expanded
Enrollment begins in DIVE study as Mt. Sinai Health System in New York City treats its first patients
Significant events after the quarter
IRRAS participates in key neurosurgery conferences
New educational webinar series announced in collaboration with Jacobs Institute and the University of Buffalo Department of Neurosurgery
Q3 Report 2022 – conference call and audiocast
IRRAS will host a conference call and an online presentation of its Q3 2022 interim report on November 10 at 09.00 CET. The presentation will be held in English.
The dial-in numbers for the conference call are:
Sweden: +46 8 50 51 63 86
UK: +44 203 198 4884
US: +1 412 317 6300
PIN code: 8057017#
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
President and CEO
Director, Investor Relations
+46 102 11 5172